In advance of the UK leaving the European Union on 29 March 2019, the Medicines and Healthcare products Regulatory Agency (MHRA) has released a statement detailing its preparations for the event of a no-deal Brexit scenario.
The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.
The US Food and Drug Administration has approved the new treatment Sprycel for children one year of age and older, facing a type of blood cancer known as Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) when used in combination with chemotherapy.
Entry for the PharmaTimes International Clinical Researcher of the Year competition will close for entry on the 31st January. Entries are already surpassing this time last year so enter now and join them.
Bringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases.
NHS England is urging patients to cancel appointments rather than just not show up, after news emerged that more than 15 million general practice appointments are being wasted each year because patients do not turn up and fail to warn surgeries in advance.
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).